When Ed’s back pain did not subside after visits to the chiropractor and a massage therapist, his concerns grew. When new symptoms arose, Ed visited the doctor and learned he had cancer near his spine. Ed was diagnosed with small cell lung cancer (SCLC), which can be aggressive. Throughout his journey he prioritized staying positive and establishing a solid care team.

As we continue to advance our work in biliary tract cancer, we’re focused on reaching patients where they are, which will help inform our approach to R&D and better support patients throughout their care journeys with the resources they need. Partnering with advocacy organizations is one way to connect with patients directly, and in turn, gain insights that will enrich our efforts and help us tailor resources specifically to the needs of patient populations.

When Willow, an active, healthy five-year-old began experiencing unusual symptoms like decreased appetite and fatigue, her mother, Valerie, didn’t assume the worst. But after her bloodwork came back abnormal – showing a critically low platelet count – Valerie’s concerns grew. It was around midnight the following day when a medical team from Children’s National Hospital in DC delivered the news that Willow had acute lymphoblastic leukemia (ALL).

Narcolepsy is a chronic, neurologic sleep disorder, and people living with the condition are at increased risk of developing cardiovascular (CV) and cardiometabolic (CM) comorbidities. New expert consensus recommendations provide more clarity on these risks, including obesity, diabetes, dyslipidemia as well as hypertension and offer actionable behavioral, therapeutic, and dietary strategies that aim to holistically mitigate these risks.

HER2 plays an important role in cell growth and survival, but many cancers, including gastroesophageal adenocarcinoma (GEA), can overexpress this protein, leading to uncontrolled cell growth and impacting prognosis. While not everyone diagnosed with a GEA will be HER2-positive, it is helpful to test for HER2 as the presence of this protein can help inform the treatment approach.

Bispecific antibodies are showing potential in the fight against HER2-expressing cancers. This innovative approach is designed to target two specific protein receptors, providing a new and effective way to treat aggressive forms of cancer that overexpress the HER2 protein. With their ability to simultaneously target two different antigens, bispecific antibodies offer a novel approach to treating solid tumors, including the possibility for new first-line treatments. 

Developmental and Epileptic Encephalopathies (DEEs) are a group of rare and severe epilepsies which are characterized by seizures and significant developmental delays. Most DEEs begin in early life, often in infancy, with children experiencing frequent and severe seizures, which can be of multiple types. This generates a complex clinical picture in which both developmental abnormalities and severe epilepsy contribute to the functional impairment of these children which continues into adulthood.

In this video, watch Mat Davis, PhD, Vice President, Head of Data Science, Evidence and Value Generation, discuss how we leverage focused and integrated quantitative methods in our R&D process to transform patient lives.

Establishing expert consensus treatment recommendations is imperative to providing more people with consistent care. As a leader in neuroscience, we are committed to empowering those we serve through innovative science and thoughtful real-world evidence.